Biofrontera AG provided preliminary revenue guidance for the full year ending December 31, 2021. For the year, the company expects revenue to be in the range of EUR 28.7 million to EUR 28.9 million compared to EUR 30.3 million in 2020.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.342 EUR | -1.44% | +0.88% | -14.71% |
Mar. 11 | Biofrontera Files Prospectus for Potential Secondary Stock Offerings | MT |
Mar. 05 | Medicus Pharma Names COO | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.71% | 23.57M | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock Biofrontera AG - Xetra
- News Biofrontera AG
- Biofrontera AG Provides Preliminary Revenue Guidance for the Full Year Ending December 31, 2021